Oncomed Pharma (OMED) 12.67 $OMED OncoMed Management to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 2:22 PM

Oncomed Pharma (OMED) 12.67 $OMED

OncoMed Management to Present at Two Upcoming Investment Conferences
GlobeNewswire - Mon Jun 06, 7:00AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, today announced that company management will participate in the following upcoming investor conferences:
OMED: 12.67 (+0.06)

OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 8:00AM CDT
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab
OMED: 12.67 (+0.06)

OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:04PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 12.67 (+0.06)

Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 49.25 (+1.08), OMED: 12.67 (+0.06), LGND: 114.10 (+0.27), ANIK: 50.61 (+0.34)

Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 12.67 (+0.06), AZN: 29.11 (+0.41), BXLT: 46.02 (-0.18), NKTR: 15.32 (+0.23)

Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 49.25 (+1.08), OMED: 12.67 (+0.06), ANIP: 56.22 (+3.43), ILMN: 145.57 (+4.68)

OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, will announce financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review first quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 12.67 (+0.06)

Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 12.54 (+0.30), OMED: 12.67 (+0.06), GSK: 42.36 (+0.60), BMY: 72.37 (+0.06), CELGZ: 1.45 (+0.01)

OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu Apr 21, 3:27PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
OMED: 12.67 (+0.06)

OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
OMED: 12.67 (+0.06)

OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
OMED: 12.67 (+0.06)

OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
GlobeNewswire - Thu Mar 17, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its Phase 1b clinical trial of OncoMed's investigational agent demcizumab (anti-DLL4, OMP-21M18), with Merck's anti-Programmed Cell Death 1 (PD1) therapy pembrolizumab (KEYTRUDA(R)). The combination of these agents may act as a double blockade for cancer-induced immune suppression with potential application to a number of solid tumor cancers.
OMED: 12.67 (+0.06)

OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
GlobeNewswire - Wed Mar 16, 3:30PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology therapeutic candidates in a total of five presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 16-20, 2016 in New Orleans, LA.
OMED: 12.67 (+0.06)

OncoMed Pharmaceuticals to Report Fourth Quarter and Year-End 2015 Financial Results on Thursday, March 10, 2016
GlobeNewswire - Fri Mar 04, 7:30AM CST
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology therapeutics, will announce financial results for the fourth quarter and year ended December 31, 2015 on Thursday, March 10, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review 2015 results, 2016 guidance and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 12.67 (+0.06)

Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 7:45AM CST
OncoMed Pharmaceuticals (OMED) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OMED: 12.67 (+0.06)

OncoMed Tanks on Phase II Pancreatic Cancer Study Update
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 1:30PM CST
OncoMed Pharmaceuticals' (OMED) shares plunged 45% after it provided disappointing update on its pancreatic cancer candidate tarextumab.
OMED: 12.67 (+0.06), BXLT: 46.02 (-0.18), GSK: 42.36 (+0.60), ANIK: 50.61 (+0.34)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OncoMed Pharmaceuticals, Inc.
BusinessWire - Mon Jan 25, 12:36PM CST
Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc. (NASDAQGS: OMED) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OMED: 12.67 (+0.06)

Why OncoMed Pharmaceuticals' Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jan 25, 11:53AM CST
What : Shares of OncoMed Pharmaceuticals , a clinical-stage biotech, dropped by more than 46% today on heavy volume after an independent data safety monitoring board reported that the company's midstage pancreatic cancer drug, tarextumab, doesn't...
OMED: 12.67 (+0.06), GSK: 42.36 (+0.60)

Will 2016 Be Celgene Corporation's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 25, 9:38AM CST
Image source: NIH Image Gallery via Flickr. In a year in which the stock market was relatively flat, biotech blue-chip Celgene was a noted outperformer, having gained 5.5% over the 12 months. 2015 was yet another strong year of growth for the...
OMED: 12.67 (+0.06), CELG: 100.36 (+1.13)

OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
GlobeNewswire - Mon Jan 25, 6:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB). The DSMB assessed data from 172 patients treated as of a January 6, 2016 data cutoff date.
OMED: 12.67 (+0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Helio Genomics Shakes Up Liver Cancer Detection Strategy

Rethinking Liver Cancer Detection with HelioLiver Sometimes you stumble upon a tech piece that might genuinely shake up the game. Helio Genomics just poured some serious intel at the San Antonio Liver Cancer Symposium, showcasing how their HelioLiver Dx might outgun traditional scans in sniffing out hepatocellular carcinoma (HCC). They threw down four studies revealing...

Morphe’s Auction Hits High Notes with Fine Jewelry

Luxurious Gems Steal the Spotlight When the gavel dropped at Morphy's Fine Jewelry & Watches Auction, it set the stage for a spectacular showcase of opulent treasures. The event, highlighting 632 lots and tallying over $1.8 million in sales, left bidders buzzing in anticipation of their next chance to snag a slice of elegance. Bvlgari's Serpentine Charm In the spotlight...

Poker Fans Flock to Venom PKOs and WSOP Paradise

October's High Stakes Poker Action The poker buzz right now is centered around Americas Cardroom. With $5.5 million in guarantees across two major tournaments – the No-Limit Hold'em and Pot-Limit Omaha – players are reaching for their cash, hoping to lock in big wins. Day 1B kicks off today, offering a dynamic mix of players vying for their shot at glory while taking...

ODL’s Impact Door System Wins 2026 Editors' Pick

Award-Winning Entry: ODL's Latest Triumph In a world where first impressions count, ODL, Inc. sure knows how to leave a mark. Their Impact Rated Fiberglass Entry System with Keystone Frame Technology snagged a notable spot in the 2026 Best of Products Awards by Architect's Newspaper. Let me tell you, in the building biz, accolades like these are no small potatoes. To get...

India's Women Apparel Market Grows Amid Innovation

India's Women Apparel Market on the Rise The winds of fashion change are sweeping through India, and the women's apparel market is at the heart of this sartorial hurricane. Set to explode from USD 28,786.82 million in 2024 to USD 45,491.96 million by 2032, this market is turning heads with a compound annual growth rate (CAGR) of 5.21%. What's stirring this pot, you ask?...

Greenberg Traurig Nabs Major Award for Sukuk Deal

Legal brands winning awards might seem like just another day in the office, but when a firm like Greenberg Traurig snags the Impact Deal of the Year at the IFLR Middle East Awards, it deserves more than just a shrug. We're talking about a serious feather in the cap for their Capital Markets team, who played a key role in launching Binghatti's hefty USD 1.5 billion Sukuk...

Choate's: 68 Years of Community and Family Values

Beyond Business: A Legacy of Giving Step into the world of Choate's, a renowned name in the Memphis area not just for its services in air conditioning, heating, plumbing, and electrical needs, but for its unwavering dedication to community service. For 68 years, this family-owned business has made its mark on the heart of Tennessee, spanning three generations and staying...

Navigating Career Growth Beyond Job Titles at Webinar

Hasn't it ever struck you that job titles often fence people in like some unwanted corral, keeping potential tightly leashed? Well, here's something that might shake up your thoughts a tad. University of Phoenix is teeing up a webinar titled "Beyond The Job Title: Finding Purpose and Recognizing the Value You Bring." Scheduled for October 15, 2026, this is all about...

Mastering Packaging Costs: Beyond the Box Price

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

DIFF Eyewear Opens First Flagship Store in Charleston

DIFF Eyewear: From Clicks to Bricks in Charleston Here's a tale of a brand shaking things up, jumping from the digital stratosphere right into solid ground. DIFF Eyewear has officially planted its flag in Charleston, SC, marking a bold transition from being an exclusively online player to real-world retail. October 10th rang in their first brick-and-mortar store on...